PMC:7247483 / 3206-3911 JSONTXT

{"project":"LitCovid_Glycan-Motif-Structure","denotations":[{"id":"T7","span":{"begin":48,"end":61},"obj":"https://glytoucan.org/Structures/Glycans/G93424OB"},{"id":"T8","span":{"begin":63,"end":65},"obj":"https://glytoucan.org/Structures/Glycans/G93424OB"},{"id":"T9","span":{"begin":279,"end":281},"obj":"https://glytoucan.org/Structures/Glycans/G93424OB"},{"id":"T10","span":{"begin":314,"end":316},"obj":"https://glytoucan.org/Structures/Glycans/G93424OB"},{"id":"T11","span":{"begin":499,"end":501},"obj":"https://glytoucan.org/Structures/Glycans/G93424OB"}],"text":"Table 1 Positive rates of (1,3)-β-D-glucan (G), galactomannan (GM), and Candida mannan (Mn) tests in different stages of disease and age groups in severe COVID-19 patients.\nStage of disease No. of patients tested No (%) of patients with positive results in each indicated test\nG GM Mn Total (Positive in any of G, GM, MN test)\nEarly (1–7 days) 15 3 (20.0) 1 (6.7) 0.00 (0) 20.003\nMiddle (8–14 days) 28 14.28 (4) 7.14 (2) 3.57 (1) 14.284\nLate (≥15 days) 138 18.11 (25) 7.97 (11) 1.45 (2) 25.3 (35)\nG GM Mn Total\nAge (years) No. of patients % (No) % (No) % (No) % (No)\n20–49 25 24 (6) 0.00 (0) 4.00 (1) 24.00 (6)\n50–64 57 12.28 (7) 8.77 (5) 1.75 (1) 21.05 (12)\n≥65 99 19.19 (19) 9.09 (9) 1.01 (1) 24.24 (24)"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T25","span":{"begin":154,"end":162},"obj":"Disease"}],"attributes":[{"id":"A25","pred":"mondo_id","subj":"T25","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Table 1 Positive rates of (1,3)-β-D-glucan (G), galactomannan (GM), and Candida mannan (Mn) tests in different stages of disease and age groups in severe COVID-19 patients.\nStage of disease No. of patients tested No (%) of patients with positive results in each indicated test\nG GM Mn Total (Positive in any of G, GM, MN test)\nEarly (1–7 days) 15 3 (20.0) 1 (6.7) 0.00 (0) 20.003\nMiddle (8–14 days) 28 14.28 (4) 7.14 (2) 3.57 (1) 14.284\nLate (≥15 days) 138 18.11 (25) 7.97 (11) 1.45 (2) 25.3 (35)\nG GM Mn Total\nAge (years) No. of patients % (No) % (No) % (No) % (No)\n20–49 25 24 (6) 0.00 (0) 4.00 (1) 24.00 (6)\n50–64 57 12.28 (7) 8.77 (5) 1.75 (1) 21.05 (12)\n≥65 99 19.19 (19) 9.09 (9) 1.01 (1) 24.24 (24)"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T12","span":{"begin":92,"end":97},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T13","span":{"begin":206,"end":212},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T14","span":{"begin":272,"end":276},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T15","span":{"begin":321,"end":325},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T16","span":{"begin":474,"end":476},"obj":"http://purl.obolibrary.org/obo/CLO_0053733"},{"id":"T17","span":{"begin":493,"end":495},"obj":"http://purl.obolibrary.org/obo/CLO_0001000"}],"text":"Table 1 Positive rates of (1,3)-β-D-glucan (G), galactomannan (GM), and Candida mannan (Mn) tests in different stages of disease and age groups in severe COVID-19 patients.\nStage of disease No. of patients tested No (%) of patients with positive results in each indicated test\nG GM Mn Total (Positive in any of G, GM, MN test)\nEarly (1–7 days) 15 3 (20.0) 1 (6.7) 0.00 (0) 20.003\nMiddle (8–14 days) 28 14.28 (4) 7.14 (2) 3.57 (1) 14.284\nLate (≥15 days) 138 18.11 (25) 7.97 (11) 1.45 (2) 25.3 (35)\nG GM Mn Total\nAge (years) No. of patients % (No) % (No) % (No) % (No)\n20–49 25 24 (6) 0.00 (0) 4.00 (1) 24.00 (6)\n50–64 57 12.28 (7) 8.77 (5) 1.75 (1) 21.05 (12)\n≥65 99 19.19 (19) 9.09 (9) 1.01 (1) 24.24 (24)"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T29","span":{"begin":36,"end":42},"obj":"Chemical"},{"id":"T30","span":{"begin":48,"end":61},"obj":"Chemical"},{"id":"T31","span":{"begin":63,"end":65},"obj":"Chemical"},{"id":"T33","span":{"begin":80,"end":86},"obj":"Chemical"},{"id":"T34","span":{"begin":88,"end":90},"obj":"Chemical"},{"id":"T36","span":{"begin":279,"end":281},"obj":"Chemical"},{"id":"T38","span":{"begin":282,"end":284},"obj":"Chemical"},{"id":"T40","span":{"begin":314,"end":316},"obj":"Chemical"},{"id":"T42","span":{"begin":318,"end":320},"obj":"Chemical"},{"id":"T43","span":{"begin":499,"end":501},"obj":"Chemical"},{"id":"T45","span":{"begin":502,"end":504},"obj":"Chemical"}],"attributes":[{"id":"A29","pred":"chebi_id","subj":"T29","obj":"http://purl.obolibrary.org/obo/CHEBI_37163"},{"id":"A30","pred":"chebi_id","subj":"T30","obj":"http://purl.obolibrary.org/obo/CHEBI_27680"},{"id":"A31","pred":"chebi_id","subj":"T31","obj":"http://purl.obolibrary.org/obo/CHEBI_74120"},{"id":"A32","pred":"chebi_id","subj":"T31","obj":"http://purl.obolibrary.org/obo/CHEBI_27680"},{"id":"A33","pred":"chebi_id","subj":"T33","obj":"http://purl.obolibrary.org/obo/CHEBI_28808"},{"id":"A34","pred":"chebi_id","subj":"T34","obj":"http://purl.obolibrary.org/obo/CHEBI_18291"},{"id":"A35","pred":"chebi_id","subj":"T34","obj":"http://purl.obolibrary.org/obo/CHEBI_28808"},{"id":"A36","pred":"chebi_id","subj":"T36","obj":"http://purl.obolibrary.org/obo/CHEBI_74120"},{"id":"A37","pred":"chebi_id","subj":"T36","obj":"http://purl.obolibrary.org/obo/CHEBI_27680"},{"id":"A38","pred":"chebi_id","subj":"T38","obj":"http://purl.obolibrary.org/obo/CHEBI_18291"},{"id":"A39","pred":"chebi_id","subj":"T38","obj":"http://purl.obolibrary.org/obo/CHEBI_28808"},{"id":"A40","pred":"chebi_id","subj":"T40","obj":"http://purl.obolibrary.org/obo/CHEBI_74120"},{"id":"A41","pred":"chebi_id","subj":"T40","obj":"http://purl.obolibrary.org/obo/CHEBI_27680"},{"id":"A42","pred":"chebi_id","subj":"T42","obj":"http://purl.obolibrary.org/obo/CHEBI_141442"},{"id":"A43","pred":"chebi_id","subj":"T43","obj":"http://purl.obolibrary.org/obo/CHEBI_74120"},{"id":"A44","pred":"chebi_id","subj":"T43","obj":"http://purl.obolibrary.org/obo/CHEBI_27680"},{"id":"A45","pred":"chebi_id","subj":"T45","obj":"http://purl.obolibrary.org/obo/CHEBI_18291"},{"id":"A46","pred":"chebi_id","subj":"T45","obj":"http://purl.obolibrary.org/obo/CHEBI_28808"}],"text":"Table 1 Positive rates of (1,3)-β-D-glucan (G), galactomannan (GM), and Candida mannan (Mn) tests in different stages of disease and age groups in severe COVID-19 patients.\nStage of disease No. of patients tested No (%) of patients with positive results in each indicated test\nG GM Mn Total (Positive in any of G, GM, MN test)\nEarly (1–7 days) 15 3 (20.0) 1 (6.7) 0.00 (0) 20.003\nMiddle (8–14 days) 28 14.28 (4) 7.14 (2) 3.57 (1) 14.284\nLate (≥15 days) 138 18.11 (25) 7.97 (11) 1.45 (2) 25.3 (35)\nG GM Mn Total\nAge (years) No. of patients % (No) % (No) % (No) % (No)\n20–49 25 24 (6) 0.00 (0) 4.00 (1) 24.00 (6)\n50–64 57 12.28 (7) 8.77 (5) 1.75 (1) 21.05 (12)\n≥65 99 19.19 (19) 9.09 (9) 1.01 (1) 24.24 (24)"}

{"project":"LitCovid-sentences","denotations":[{"id":"T23","span":{"begin":0,"end":172},"obj":"Sentence"},{"id":"T24","span":{"begin":173,"end":276},"obj":"Sentence"},{"id":"T25","span":{"begin":277,"end":326},"obj":"Sentence"},{"id":"T26","span":{"begin":327,"end":379},"obj":"Sentence"},{"id":"T27","span":{"begin":380,"end":436},"obj":"Sentence"},{"id":"T28","span":{"begin":437,"end":496},"obj":"Sentence"},{"id":"T29","span":{"begin":497,"end":510},"obj":"Sentence"},{"id":"T30","span":{"begin":511,"end":566},"obj":"Sentence"},{"id":"T31","span":{"begin":567,"end":610},"obj":"Sentence"},{"id":"T32","span":{"begin":611,"end":658},"obj":"Sentence"},{"id":"T33","span":{"begin":659,"end":705},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Table 1 Positive rates of (1,3)-β-D-glucan (G), galactomannan (GM), and Candida mannan (Mn) tests in different stages of disease and age groups in severe COVID-19 patients.\nStage of disease No. of patients tested No (%) of patients with positive results in each indicated test\nG GM Mn Total (Positive in any of G, GM, MN test)\nEarly (1–7 days) 15 3 (20.0) 1 (6.7) 0.00 (0) 20.003\nMiddle (8–14 days) 28 14.28 (4) 7.14 (2) 3.57 (1) 14.284\nLate (≥15 days) 138 18.11 (25) 7.97 (11) 1.45 (2) 25.3 (35)\nG GM Mn Total\nAge (years) No. of patients % (No) % (No) % (No) % (No)\n20–49 25 24 (6) 0.00 (0) 4.00 (1) 24.00 (6)\n50–64 57 12.28 (7) 8.77 (5) 1.75 (1) 21.05 (12)\n≥65 99 19.19 (19) 9.09 (9) 1.01 (1) 24.24 (24)"}

{"project":"LitCovid-PD-GlycoEpitope","denotations":[{"id":"T7","span":{"begin":48,"end":61},"obj":"GlycoEpitope"},{"id":"T8","span":{"begin":63,"end":65},"obj":"GlycoEpitope"},{"id":"T9","span":{"begin":279,"end":281},"obj":"GlycoEpitope"},{"id":"T10","span":{"begin":314,"end":316},"obj":"GlycoEpitope"},{"id":"T11","span":{"begin":499,"end":501},"obj":"GlycoEpitope"}],"attributes":[{"id":"A7","pred":"glyco_epitope_db_id","subj":"T7","obj":"http://www.glycoepitope.jp/epitopes/EP0510"},{"id":"A8","pred":"glyco_epitope_db_id","subj":"T8","obj":"http://www.glycoepitope.jp/epitopes/EP0510"},{"id":"A9","pred":"glyco_epitope_db_id","subj":"T9","obj":"http://www.glycoepitope.jp/epitopes/EP0510"},{"id":"A10","pred":"glyco_epitope_db_id","subj":"T10","obj":"http://www.glycoepitope.jp/epitopes/EP0510"},{"id":"A11","pred":"glyco_epitope_db_id","subj":"T11","obj":"http://www.glycoepitope.jp/epitopes/EP0510"}],"text":"Table 1 Positive rates of (1,3)-β-D-glucan (G), galactomannan (GM), and Candida mannan (Mn) tests in different stages of disease and age groups in severe COVID-19 patients.\nStage of disease No. of patients tested No (%) of patients with positive results in each indicated test\nG GM Mn Total (Positive in any of G, GM, MN test)\nEarly (1–7 days) 15 3 (20.0) 1 (6.7) 0.00 (0) 20.003\nMiddle (8–14 days) 28 14.28 (4) 7.14 (2) 3.57 (1) 14.284\nLate (≥15 days) 138 18.11 (25) 7.97 (11) 1.45 (2) 25.3 (35)\nG GM Mn Total\nAge (years) No. of patients % (No) % (No) % (No) % (No)\n20–49 25 24 (6) 0.00 (0) 4.00 (1) 24.00 (6)\n50–64 57 12.28 (7) 8.77 (5) 1.75 (1) 21.05 (12)\n≥65 99 19.19 (19) 9.09 (9) 1.01 (1) 24.24 (24)"}